Lv4
691 积分 2021-06-02 加入
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
14小时前
已完结
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
14小时前
已完结
Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
2天前
已完结
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
17天前
已完结
BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease
17天前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
21天前
已完结
In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus
21天前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
21天前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
28天前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
1个月前
已完结
皖公网安备34019202002308
